303 related articles for article (PubMed ID: 36077166)
1. Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity.
Chen PW; Tseng SY; Chang HY; Lee CH; Chao TH
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077166
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
[TBL] [Abstract][Full Text] [Related]
3. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
4. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
Ruscica M; Ricci C; Macchi C; Magni P; Cristofani R; Liu J; Corsini A; Ferri N
J Biol Chem; 2016 Feb; 291(7):3508-19. PubMed ID: 26668321
[TBL] [Abstract][Full Text] [Related]
5. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
6. Schisandrin A in
Kim HJ; Park SK; Park SH; Lee YG; Park JH; Hwang JT; Chung MY
J Microbiol Biotechnol; 2024 Feb; 34(2):425-435. PubMed ID: 37997262
[No Abstract] [Full Text] [Related]
7. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
8. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
[TBL] [Abstract][Full Text] [Related]
9. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D
J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270
[TBL] [Abstract][Full Text] [Related]
10. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.
Sun H; Meng W; Zhu J; Wang L
Naunyn Schmiedebergs Arch Pharmacol; 2022 Jun; 395(6):643-658. PubMed ID: 35307759
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
[TBL] [Abstract][Full Text] [Related]
14. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.
Tao R; Xiong X; DePinho RA; Deng CX; Dong XC
J Biol Chem; 2013 Oct; 288(41):29252-9. PubMed ID: 23974119
[TBL] [Abstract][Full Text] [Related]
15. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.
Katsuki S; K Jha P; Lupieri A; Nakano T; Passos LSA; Rogers MA; Becker-Greene D; Le TD; Decano JL; Ho Lee L; Guimaraes GC; Abdelhamid I; Halu A; Muscoloni A; V Cannistraci C; Higashi H; Zhang H; Vromman A; Libby P; Keith Ozaki C; Sharma A; Singh SA; Aikawa E; Aikawa M
Circ Res; 2022 Nov; 131(11):873-889. PubMed ID: 36263780
[TBL] [Abstract][Full Text] [Related]
16. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
Le QT; Blanchet M; Seidah NG; Labonté P
J Biol Chem; 2015 Sep; 290(38):23385-400. PubMed ID: 26195630
[TBL] [Abstract][Full Text] [Related]
17. Proprotein convertase subtilisin/kexin 9 inhibitor downregulates microRNA-130a-3p expression in hepatocytes to alleviates atherosclerosis progression.
Xu J; Zuo J; Han C; Li T; Jin D; Zhao F; Cong H
Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1727-1736. PubMed ID: 37721554
[TBL] [Abstract][Full Text] [Related]
18. Non-hematopoietic deficiency of proprotein convertase subtilisin/kexin type 9 deficiency leads to more severe anemia in a murine model of sickle cell disease.
Venugopal J; Wang J; Guo C; Lu H; Chen YE; Eitzman DT
Sci Rep; 2020 Oct; 10(1):16514. PubMed ID: 33020528
[TBL] [Abstract][Full Text] [Related]
19. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
